Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV103
- Development stage
- Preclinical
- Lead developer
- Sysvax
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
SV103 is a recombinant protein-based in vivo diagnostic reagent under development by Sysvax for the diagnosis of tuberculosis. It is designed to be used as a skin test to detect *Mycobacterium tuberculosis* infection by eliciting a delayed-type hypersensitivity (DTH) response. By utilizing specific recombinant antigens that are absent in the *Bacillus Calmette-Guérin* (BCG) vaccine and most non-tuberculous mycobacteria, SV103 aims to provide a more specific alternative to the traditional tuberculin skin test (TST), which often yields false-positive results in BCG-vaccinated individuals. The reagent is currently in the preclinical stage of development.
Beyond the preview
Go deeper on SV103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV103.